Title |
CRISPR-Cas9 disruption of PD-1 enhances activity of universal EGFRvIII CAR T cells in a preclinical model of human glioblastoma
|
---|---|
Published in |
Journal for Immunotherapy of Cancer, November 2019
|
DOI | 10.1186/s40425-019-0806-7 |
Pubmed ID | |
Authors |
Bryan D. Choi, Xiaoling Yu, Ana P. Castano, Henia Darr, Daniel B. Henderson, Amanda A. Bouffard, Rebecca C. Larson, Irene Scarfò, Stefanie R. Bailey, Genevieve M. Gerhard, Matthew J. Frigault, Mark B. Leick, Andrea Schmidts, Jason G. Sagert, William T. Curry, Bob S. Carter, Marcela V. Maus |
X Demographics
The data shown below were collected from the profiles of 26 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
Country | Count | As % |
---|---|---|
United States | 16 | 62% |
Germany | 2 | 8% |
Unknown | 8 | 31% |
Demographic breakdown
Type | Count | As % |
---|---|---|
Members of the public | 14 | 54% |
Scientists | 7 | 27% |
Practitioners (doctors, other healthcare professionals) | 3 | 12% |
Science communicators (journalists, bloggers, editors) | 2 | 8% |
Mendeley readers
The data shown below were compiled from readership statistics for 266 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
Country | Count | As % |
---|---|---|
Unknown | 266 | 100% |
Demographic breakdown
Readers by professional status | Count | As % |
---|---|---|
Researcher | 38 | 14% |
Student > Master | 37 | 14% |
Student > Bachelor | 37 | 14% |
Student > Ph. D. Student | 36 | 14% |
Student > Doctoral Student | 14 | 5% |
Other | 20 | 8% |
Unknown | 84 | 32% |
Readers by discipline | Count | As % |
---|---|---|
Biochemistry, Genetics and Molecular Biology | 50 | 19% |
Immunology and Microbiology | 34 | 13% |
Medicine and Dentistry | 28 | 11% |
Agricultural and Biological Sciences | 23 | 9% |
Engineering | 10 | 4% |
Other | 27 | 10% |
Unknown | 94 | 35% |
Attention Score in Context
This research output has an Altmetric Attention Score of 29. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 03 November 2022.
All research outputs
#1,374,185
of 25,540,105 outputs
Outputs from Journal for Immunotherapy of Cancer
#343
of 3,454 outputs
Outputs of similar age
#29,242
of 375,539 outputs
Outputs of similar age from Journal for Immunotherapy of Cancer
#10
of 95 outputs
Altmetric has tracked 25,540,105 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 94th percentile: it's in the top 10% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 3,454 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 15.7. This one has done particularly well, scoring higher than 90% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 375,539 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 92% of its contemporaries.
We're also able to compare this research output to 95 others from the same source and published within six weeks on either side of this one. This one has done well, scoring higher than 89% of its contemporaries.